StockWatch
·
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Quarterly ResultMay 12, 2026, 04:19 PM

Hyperfine Q1 Sales +82.6% to $3.9M; Net Loss Narrows to $(8.6)M

AI Summary

Hyperfine, Inc. reported a significant increase in total sales for Q1 2026, up 82.6% to $3.9 million, driven by strong device sales. The net loss narrowed to $(8.6) million from $(9.4) million in Q1 2025. The company also secured several regulatory approvals for its Swoop® system and Optive AI™ software in the US, EU, UK, and India, and obtained $13.6 million in net debt proceeds. Despite improved financials, the company continues to operate with a going concern warning.

Key Highlights

  • Total sales increased 82.6% to $3.9 million in Q1 2026 from $2.1 million in Q1 2025.
  • Device sales grew 114% to $3.3 million in Q1 2026 from $1.5 million in Q1 2025.
  • Net loss narrowed to $(8.6) million in Q1 2026 from $(9.4) million in Q1 2025.
  • Net loss per common share improved to $(0.09) in Q1 2026 from $(0.12) in Q1 2025.
  • Gross profit increased 124% to $2.0 million in Q1 2026 from $0.9 million in Q1 2025.
  • Cash and cash equivalents rose to $40.8 million as of March 31, 2026, from $35.1 million at December 31, 2025.
  • Net cash provided by financing activities was $14.5 million in Q1 2026, including $13.6 million from debt.
  • Received CE Mark and UKCA Mark approval for next-gen Swoop® scanner and Optive AI™ software in March 2026.